Carlos Guimarães is the CEO at Biocancer Clinical Research in Brazil. Biocancer is an oncology-focused drug development services company which assists pharmaceutical, biotechnology, medical device and drug development services companies in accessing Brazil's large patient populations. Since 2006, he is responsible for the general administration of the company, including its strategic realignment for venture capital investment.
Previously, Guimarães was the director of a successful Brazilian biotech company where he was responsible for national and international expansion. He has a broad international experience, a strong ability to lead teams, and exceptional performance in the commercial area. Over the last 10 years he has been running different business and since May 2006, was in charge of leading Biocancer to a distinguished position in clinical trials in the world.
Carlos Guimaraes graduated with a degree in Business Administration from Federal University of Minas Gerais (UFMG) Brazil, and received his MBA Executive International degree at Fundação Dom Cabral (Brazil & Sauder Business School (Canada).
I find this work very interesting. In other words, they do not come from a specific socioeconomic group or standard. We have people in Class A, B, C, D ... Why? These are people who may not have any therapeutic option other than clinical trials. So how do we recruit people today? The partner phys...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login